Indication: Glioblastoma

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination with Bevacizumab versus Bevacizumab Alone in Patients with Recurrent or Progressive Glioblastoma following Initial Therapy

Recurrent or Progressive

Sub-indication: Glioblastoma Multiforme

Line of Therapy: Second line post TMZ

Drug Study

Principal Investigator: Renato LaRocca, M.D.
Norton Cancer Institute

Sponsor: Boston Biomedical, Inc.

Learn more at ClinicalTrials.gov

Email for more information: CNS-NCIResearch@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.